Select older patients can undergo HCT, according to results of a study of 54 consecutive patients >70 years undergoing reduced-intensity transplantation between 2007 and 2012 at Massachusetts General Hospital (n=14) or the Dana-Farber Cancer Institute (n=40). Median age at transplantation was 71 years (range, 70 to 76), and the median HCT comorbidity index score was 1 (range, 0 to 5). Day-100 non-relapse mortality (NRM) was 3.7% and two-year NRM was 5.6%. Two-year cumulative incidence of chronic GVHD was 36%, and progression-free and overall survival were both 39%.
Brunner AM, et al. Biol Blood Marrow Transplant